Hematologic Malignancy
B Lymphoblastic Leukemia/Lymphoma
CI-CAN-00000469Explore in graph →
Hematologic163 active trials1 approved drugs180 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000469Explore in graph →
Clinical trials
373 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (49)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02228096 | Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients(ENSIGN) | completed | Phase 2 | 75 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 23, 2020 | clinicaltrials |
| NCT01258998 | Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Nov 4, 2020 | clinicaltrials |
| NCT01914484 | Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia | completed | Phase 1 / Phase 2 | 4 | University Health Network, TorontoOTHER | 1 | Nov 2, 2020 | clinicaltrials |
| NCT03097770 | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20 | completed | Phase 1 / Phase 2 | 100 | Chinese PLA General HospitalOTHER | 1 | Sep 2, 2020 | clinicaltrials |
| NCT00720109 | Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | completed | Phase 2 / Phase 3 | 63 | National Cancer Institute (NCI)NIH | 5 | Apr 13, 2020 | clinicaltrials |
| NCT00918333 | Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 124 | Mayo ClinicOTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT01207388 | Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)(BLAST) | completed | Phase 2 | 116 | Amgen Research (Munich) GmbHINDUSTRY | 11 | Feb 10, 2020 | clinicaltrials |
| NCT01326702 | Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors | completed | Phase 1 / Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2019 | clinicaltrials |
| NCT02228772 | Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults | completed | Phase 1 | 19 | Massachusetts General HospitalOTHER | 1 | Nov 26, 2019 | clinicaltrials |
| NCT02652715 | Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma | completed | N/A | 29 | Mayo ClinicOTHER | 1 | Nov 15, 2019 | clinicaltrials |
| NCT00382109 | Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission | completed | Phase 3 | 146 | Children's Oncology GroupNETWORK | 3 | Aug 7, 2019 | clinicaltrials |
| NCT03821727 | SCT in Ph Positive Acute Lymphoblastic Leukemia | completed | — | 441 | CANDONI ANNAOTHER | 1 | Jan 30, 2019 | clinicaltrials |
| NCT01093586 | Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 14 | Case Comprehensive Cancer CenterOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT01769209 | Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia | completed | Phase 2 | 18 | Stanford UniversityOTHER | 1 | Nov 14, 2018 | clinicaltrials |
| NCT01567709 | Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma | completed | Phase 1 | 34 | National Cancer Institute (NCI)NIH | 1 | Apr 11, 2018 | clinicaltrials |
| NCT00867529 | Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma | completed | Phase 2 | 63 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 2, 2018 | clinicaltrials |
| NCT01786135 | A Safety Study of SGN-CD19A for B-Cell Lymphoma | completed | Phase 1 | 64 | Seagen Inc.INDUSTRY | 1 | Oct 19, 2017 | clinicaltrials |
| NCT01116193 | Repeat-dose Study of Lenalidomide (Revlimid ®) Plus Dexamethasone in Patients With Lymphoblastic Leukemia(RV-405 LAL) | completed | Phase 2 | 10 | Institut de Cancérologie de la LoireOTHER | 1 | Sep 14, 2017 | clinicaltrials |
| NCT00702403 | Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML | completed | Phase 1 / Phase 2 | 40 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 10, 2017 | clinicaltrials |
| NCT00437060 | Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia | completed | — | 233 | Children's Oncology GroupNETWORK | 4 | Jul 21, 2017 | clinicaltrials |
| NCT01786096 | A Safety Study of SGN-CD19A for Leukemia and Lymphoma | completed | Phase 1 | 92 | Seagen Inc.INDUSTRY | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00052520 | Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation | completed | Phase 1 / Phase 2 | 37 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 29, 2017 | clinicaltrials |
| NCT01209286 | Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL) | completed | Phase 2 | 36 | Amgen Research (Munich) GmbHINDUSTRY | 1 | Mar 6, 2017 | clinicaltrials |
| NCT00873093 | Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | completed | Phase 2 | 148 | National Cancer Institute (NCI)NIH | 4 | Jan 27, 2017 | clinicaltrials |
| NCT01540578 | Studying Biomarkers as a Diagnostic Tool in Samples From Younger Patients With B-Cell Acute Lymphoblastic Leukemia | completed | — | 70 | Children's Oncology GroupNETWORK | 1 | May 18, 2016 | clinicaltrials |
| NCT01625143 | Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia | completed | — | 40 | Children's Oncology GroupNETWORK | 1 | May 18, 2016 | clinicaltrials |
| NCT00898404 | Response or Resistance to Chemotherapy in Young Patients With Acute Lymphoblastic Leukemia Treated With Methotrexate | completed | — | 150 | Children's Oncology GroupNETWORK | 1 | May 11, 2016 | clinicaltrials |
| NCT00111683 | MK0457 in Patients With Leukemia (0457-003) | completed | Phase 1 | 28 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 25, 2015 | clinicaltrials |
| NCT01403415 | Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma | completed | Phase 1 | 13 | National Cancer Institute (NCI)NIH | 2 | Jul 10, 2015 | clinicaltrials |
| NCT00608361 | Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery | completed | Phase 1 | 80 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2015 | clinicaltrials |
| NCT01290120 | Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin Lymphoma | completed | Phase 2 | 182 | Northern Italy Leukemia GroupOTHER | 1 | Sep 16, 2014 | clinicaltrials |
| NCT00010192 | Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2013 | clinicaltrials |
| NCT00822432 | Coproporphyrine Isomers and Methotrexate Elimination(COMETH) | completed | — | 85 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jul 31, 2012 | clinicaltrials |
| NCT00289562 | Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia | completed | Phase 1 / Phase 2 | 20 | BioCryst PharmaceuticalsINDUSTRY | 1 | Jan 20, 2012 | clinicaltrials |
Data updated 22 days agoSource updated Nov 23, 2020source: clinicaltrials